Skip to content
Subscriber Only
Markets
Deals

Valeant Said to Be in Talks for Sale of Salix to Takeda

  • Drugmaker confirms it’s in talks, doesn’t say with who
  • Business could go for as much as $10 billion, WSJ reports
Video player cover image

Valeant Said in Talks for Salix Sale

Updated on

Valeant Pharmaceuticals International Inc. is in talks to sell its Salix gastrointestinal drugs business to Japan’s Takeda Pharmaceutical Co., according to a person familiar with the matter.

The unit could go for as much as $10 billion and there is at least one other bidder interested, the Wall Street Journal reported earlier. The deal would include at least $8.5 billion in cash, the Journal said, plus future royalty payments.